All In Biotech

Drug Trial Radar · NCT05938699

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution - A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial (Whistler)

Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

18

Actual

Start

Dec 12, 2023

Primary completion

Mar 17, 2025

Study completion Mar 17, 2025

Sponsor

Lead sponsor
Nicox Ophthalmics, Inc.Industry
Sponsor type
Industry
First posted
Jul 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a double-masked, placebo-controlled study which will determine the action of NCX 470 ophthalmic solution, 0.1% on aqueous humor dynamic parameters in healthy volunteers or subjects with OHT.

Conditions

  • Open Angle Glaucoma

Interventions

  • NCX 470Drug

    NCX 470 0.1% vs Placebo

  • PlaceboDrug

    NCX 0.1% vs Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in AHDTime frame: 8 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.